Inclusion Criteria:  All patients admitted at the COVID-19 non-ICU with a diagnosis of Type 2 or Secondary diabetes mellitus (DM) for whom intensive insulin therapy (basal plus at least two boluses) is indicated are eligible for the study.  Exclusion Criteria:  Patients on hydroxyurea treatment are excluded (interference with glucose sensor readings).